Cytomegalovirus as a novel target for immunotherapy of glioblastoma multiforme
Progress in the treatment of glioblastoma multiforme (GBM) over the last few decades has remained marginal and GBM is still universally fatal with short survival times after initial diagnosis. Much research is focused on finding new therapeutics for GBM and immune based approaches have shown great p...
Main Authors: | Andrea eSchuessler, David eWalker, Rajiv eKhanna |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2014-10-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | http://journal.frontiersin.org/Journal/10.3389/fonc.2014.00275/full |
Similar Items
-
Editorial: Improving responses to immunotherapy in glioblastoma multiforme
by: Stephanie E. B. McArdle, et al.
Published: (2024-04-01) -
Impact of pre‐therapy glioblastoma multiforme microenvironment on clinical response to autologous CMV‐specific T‐cell therapy
by: David G Walker, et al.
Published: (2019-01-01) -
Current Understanding of Hypoxia in Glioblastoma Multiforme and Its Response to Immunotherapy
by: Jang Hyun Park, et al.
Published: (2022-02-01) -
The Basis and Advances in Clinical Application of Cytomegalovirus-Specific Cytotoxic T Cell Immunotherapy for Glioblastoma Multiforme
by: Amin Daei Sorkhabi, et al.
Published: (2022-04-01) -
Immune Escape in Glioblastoma Multiforme and the Adaptation of Immunotherapies for Treatment
by: Joshua R. D. Pearson, et al.
Published: (2020-10-01)